Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 737-738

  Spriet, Isabel ^a   Grootaert, Veerle ^a   Meyfroidt, Geert ^a   Debaveye, Yves ^a   Willems, Ludo ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BASILIXIMAB; BILIRUBIN; CYCLODEXTRIN; CYTOCHROME P450 3A4; ITRACONAZOLE; KETOCONAZOLE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ABNORMAL LABORATORY RESULT; ADULT; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BILIRUBIN BLOOD LEVEL; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INTOXICATION; DRUG POTENTIATION; GRAFT REJECTION; HUMAN; INTENSIVE CARE UNIT; LETTER; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MALE; PH; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PULMONARY ASPERGILLOSIS; PYRIMIDINES; TACROLIMUS; TRIAZOLES;

EID: 84877129329     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1365-8     Document Type: Letter

References (11)

1. Pfizer Inc. (2003) Vfend (voriconazole) package insert. New York, NY
2. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I (1999) Effect of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39:91-96
3. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF (1997) Tacrolimus oral bio-availability doubles with co-administration of ketoconazole. Clin Pharmacol Ther 62:41-49
4. Zhang S, Pillai VC, Mada SR, Strom S, Venkataramanan R (2012) Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 42:409-416
5. Saad AH, DePestel D, Carver PL (2006) Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacother 26:1730-1744
6. Inoue Y, Saito T, Taikimoto M, Ogawa K, Shibuya Y, Suzuki Y, Kato M, Takahashi M, Miura I, Hatta Y, Takeuchi J (2011) Highly activated oral bioavailability of tacrolimus on coadministration of oral voriconazole. Int J Clin Pharmacol Ther 49:291-292
7. Mori T, Kato J, Yamane A, Sakurai M, Kohashi S, Kikuchi T, Ono Y, Okamoto S (2012) Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoetic stem cell transplantation. Int J Hematol 95:564-569
8. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, Kusuhara H, Ito K, Sugiyama Y (2003) The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein. Quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372
9. Purkins L, Wood N, Kleinermans D, Nichols D (2003) Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol 56:45-50
10. Kramer MR, Amital A, Fuks L, Shitrit D (2011) Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. Clin Transplant 25:E163-E167
11. Venkataramanan R, Zang S, Gayowski T, Singh N (2002) Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agent Chemother 46:3091-3093